Data collected from cerebrospinal fluid (CSF) biomarkers and positron emission tomography (PET) imaging from AD patients indicate that Aβ is the first biomarker to accumulate, followed by the appearance of synaptic dysfunction and increased tau-protein concentrations3. The gene discussed is MAPT; the disease is Alzheimer disease.